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Scott Bilder, PhD, Sepheen C. Byron, MHS, Sarah Hudson Scholle, MPH, DrPH,
Stephen Crystal, PhD, Mark Olfson, MD, MPHObjective: To examine rates and predictors of receiving a
psychosocial service before initiating antipsychotic treat-
ment among young people in the Medicaid program.
Method: A retrospective new-user cohort study of 8 state
Medicaid programs focused on children and adolescents 0 to
20 years, initiating antipsychotic treatment (N ¼ 24,372).
The proportion receiving a psychosocial service in the
3 months before initiating antipsychotic treatment was
calculated and stratiﬁed by socio-demographic and diag-
nostic characteristics arranged in 9 hierarchical groups,
as follows: developmental, psychotic/bipolar, disruptive,
attention-deﬁcit/hyperactivity, obsessive-compulsive, stress,
major depressive, anxiety, and other disorders.
Results: Less than one-half of youth received a psycho-
social service before initiating antipsychotic treatment
(48.8%). Compared to younger adolescents (12–17 years)
initiating antipsychotic treatment (51.5%), corresponding
younger children (0–5 years; 39.2%) and older adolescents
(18–20 years; 40.1%), but not older children (6–11 years;
51.5%), were signiﬁcantly less likely to have received aThis article can be used to obtain continuing medical education (CME)
at www.jaacap.org.
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E 55 NUMBER 1 JANUARY 2016psychosocial service. In relation to youth diagnosed with
psychotic or bipolar disorder (52.7%), those diagnosed
with attention-deﬁcit/hyperactivity (43.3%), develop-
mental (41.4%), depressive (46.5%), or anxiety (35.6%)
disorder were signiﬁcantly less likely to have received a
psychosocial service during the 3 months before antipsy-
chotic initiation. By contrast, youth diagnosed with stress
disorders (61.2%) were signiﬁcantly more likely than those
diagnosed with psychotic or bipolar disorders (52.7%) to
have received a psychosocial service before starting an
antipsychotic.
Conclusion: A majority of Medicaid-insured youth initi-
ating antipsychotic treatment have not received a psy-
chosocial service in the preceding 3 months. This service
pattern highlights a critical gap in access to psychosocial
services.
Key words: psychotherapy, access to care, antipsychotic
treatment, prescribing practices, children
J Am Acad Child Adolesc Psychiatry 2016;55(1):69–76.he use of antipsychotic medications for children and
adolescents has increased sharply in the era of second-T generation antipsychotics.1-4 Clinical trials support the
efﬁcacy of several antipsychotics for bipolar mania in chil-
dren and adolescents,5 schizophrenia in adolescents,6 and
irritability associated with autistic disorder in adolescents
and children.7 In practice, however, antipsychotics are often
used for a wider range of disorders, including the manage-
ment of disruptive behaviors and aggression in the context
of attention-deﬁcit/hyperactivity disorder8 (ADHD) and
disruptive, impulse-control, and conduct disorders.9 In one
study of 208 antipsychotic-treated children aged 2–15 years,
the prescribing physicians indicated that the target symp-
toms were most commonly aggression (47%), behavioral
difﬁculties (26%), and anxiety (17%), and less commonly
hyperactivity (10%), mood disturbances (9%), psychotic
symptoms (7%), and other symptoms.10 In a recent
national study of Medicaid-enrolled children, the use ofantipsychotics increased 62% between 2002 and 2007; by
2007, ADHD was the leading diagnosis, representing 50% of
children on antipsychotics.11 Only about one-third (33%) of
second-generation antipsychotic prescriptions to young
people in the United States are for disorders for which there
is at least good or moderate evidence of antipsychotic
effectiveness.12
In view of widespread antipsychotic medication pre-
scription to young people for conditions without strong sup-
porting clinical evidence, concerns have been raised over the
effects of antipsychotic medications on their cardiovascular
and metabolic health.13,14 Given the established health risks
associated with antipsychotic medications, attention has also
focused on strategies to minimize unnecessary antipsychotic
treatment of children and adolescents.15 An increased role for
evidence-based psychosocial and behavioral interventions
early in the course of treatment for children who present with
externalizing problems has been suggested as one means of
potentially reducing clinical treatmentwith antipsychotics for
nonpsychotic disorders in young people.16,17
Externalizing symptoms are widely distributed across
psychiatric disorders in clinical populations.18 A substantial
body of clinical research supports the efﬁcacy of outpatient
psychosocial treatments for disruptive behavior problems in
children and adolescents. A meta-analysis of 32 controlledwww.jaacap.org 69
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ductions in teacher-reported aggression and improved social
function with stronger effects associated with behavior
therapy than with family therapy, although the literature is
better developed for children than for adolescents.19 In
children less than 8 years of age, a recent meta-analysis of 36
controlled trials further demonstrated large and sustained
beneﬁcial effects of parent–child interaction therapy, a pos-
itive parenting program, and other psychosocial treatments
on disruptive behavior problems, with especially strong
effects on externalizing problems and oppositionality.20
Even in children with autism, a meta-analysis of 34 studies
supports the effectiveness of early intensive behavioral
interventions to improve adaptive and to reduce maladap-
tive behaviors.21
The American Academy of Child and Adolescent Psy-
chiatry (AACAP) Practice Parameter for the Use of Atypical
Antipsychotic Medications in Children and Adolescents
recommends that with the important exception of US Food
and Drug Administration (FDA)–indicated conditions,
clinicians should consider psychosocial or other pharmaco-
logical interventions with established safety and efﬁcacy
proﬁles before initiating an antipsychotic.22 There are few
data available on the overall extent to which youth receive
psychosocial interventions before starting an antipsychotic
medication. Prior research in this area has been limited to
characterizing the proportion of young people receiving
antipsychotics who also receive psychosocial treatments
rather than the percentage who receive a psychosocial
intervention before starting an antipsychotic medication. In a
study of a mid–Atlantic state Medicaid-managed care plan,
for example, 68% of youth 6 to 17 years of age who were
starting treatment with an antipsychotic in 2006 to 2009
received combined medication management and psycho-
therapy.23 Among very young privately insured children
receiving an antipsychotic, the proportion receiving any
psychotherapy decreased from 50% in 1999 to 2001 to 41.4%
in 2007.24 This trend is consistent with a broader trend in US
mental health service provision toward a declining percent-
age of treated individuals receiving psychotherapy, either
alone or in combination with a psychotropic medication.
We assess patterns in access to psychosocial interventions
before initiating treatment with an antipsychotic for children
0 to 20 years of age in 8 state Medicaid programs. Given
concerns over access to psychosocial services, particularly for
children and adolescents receiving antipsychotics who have
ADHD or disruptive behavior disorders, we examine access
to psychosocial services before antipsychotic initiation,
stratiﬁed by patient characteristics and clinical diagnoses
with and without FDA indications for antipsychotic use.METHOD
Study Design and Data Source
This was a retrospective cohort study using 2008 Medicaid
Analytic eXtract (MAX) claims and managed care encounter data
from 8 states (GA, IN, KS, KY, MI, MO, NM, and RI). States were
selected based on their Medicaid data quality, including
completeness of managed care enrollees in states using managed70 www.jaacap.orgcare.25,26 The study was approved or deemed exempt from review
by the institutional review boards of New York State Psychiatric
Institute, Rutgers University, and the National Committee for
Quality Assurance.
Study Population
Medicaid-enrolled children and adolescents, 0 to 20 years of age,
with a new start of an antipsychotic, were included in the study.
A new start was deﬁned as the ﬁrst antipsychotic prescription in
2008 preceded by 120 days without any antipsychotic (see Table S1,
available online, for antipsychotics). Continuous enrollment crite-
rion was 120 days before to 30 days after antipsychotic initiation.
Medicare/Medicaid dually eligible youth were excluded. The un-
duplicated number of young persons meeting eligibility criteria was
24,372.
Deﬁnitions and Measures
Young people were grouped into 4 age categories: younger children
(0–5 years), older children (6–12 years), younger adolescents (13–17
years), and older adolescents (18–20 years). Race/ethnicity cate-
gories were white non-Hispanic, African American non-Hispanic,
Hispanic, and other. Managed care status was categorized as any
versus no managed care. County of residence was categorized as
metropolitan, non-metropolitan urban, and rural, by merging MAX
county of residence with the Area Resource File Rural-Urban Con-
tinuum Code (2003).27 Eligibility categories were foster care, income
based, Supplemental Security Income, and other. Behavioral health
hospital use was deﬁned as any hospitalization with a behavioral
health diagnosis during 2008.
Young people were assigned to 1 of 16 hierarchical diagnoses
based on an examination of all diagnoses associated with any
claim or encounter in 2008 (see Table S2, available online). The
hierarchical ordering is based on FDA indications and data on
antipsychotic prescribing practices for young people to identify
the diagnosis most likely to be the target for the antipsychotic
treatment.3,11 These 16 diagnostic groups (indicated in parenthe-
ses) were subsequently aggregated into 9 diagnostic categories, as
follows: developmental and tic disorders (#1–2); psychotic or bi-
polar disorders (#3–5); disruptive behavior disorders (#6–8);
ADHD (#9); stress disorders (posttraumatic stress disorder [PTSD]
#10, and adjustment disorder #14); obsessive-compulsive disorder
(OCD, #11); major depressive disorder (MDD, #12); anxiety dis-
order (#13); and substance use disorder or other mental health
disorders (#15–16).
An outpatient psychosocial service prior to a new start of an
antipsychotic was the outcome measure. Youth with 1 or more
psychosocial services within 90 days before starting an antipsychotic
medication were identiﬁed using Current Procedural Terminology
(CPT) codes, including individual, group, and family psychother-
apy, intensive outpatient, and other psychosocial interventions (see
Table S3, available online, for CPT codes used). We selected 90 days
before antipsychotic initiation based in part on measure testing;
extending the window to 120 days identiﬁed only 1.3% more
additional children with psychosocial services.
Data Analysis
Analyses were performed using SAS, version 9.2 (SAS Institute,
Cary, NC). Descriptive statistics were calculated for the cohort of
young people with a new start of an antipsychotic. Prevalence of a
psychosocial visit before a new start of an antipsychotic was
calculated for children with 1 or more mental health diagnoses for
each of the 16 diagnostic groups, 9 diagnostic categories, and all
other covariates examined. Exact (Clopper–Pearson) conﬁdenceJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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TABLE 1 Characteristics of Medicaid-Insured Children and
Adolescents With a New Start of Antipsychotic Medication
Characteristic
% of Total
(N ¼ 24,372)
Age, y
0e5 7.10
6e11 33.91
12e17 46.55
18e20 12.44
Sex
Female 36.09
Male 63.91
Race/ethnicity
White non-Hispanic 64.16
African American 22.28
Hispanic 4.13
Other/unknown 9.43
Managed care
Enrollee 74.56
None 25.44
Urbanicity
Metropolitan 69.33
Non-metropolitan urban 26.37
Rural 3.84
Eligibility category
Foster 15.59
Income 56.46
Other 4.15
SSI 23.80
MH
Hospitalization
Yes 11.43
No 88.57
MH diagnosisa
Any MH diagnosis 93.65
No MH diagnosis 6.35
TABLE 1 Continued
Characteristic
% of Total
(N ¼ 24,372)
Developmental and tic
disorders
8.04
Autism and PDD (1) 7.40
Tic disorders (2) 0.64
Psychotic and bipolar
disorders
25.53
Schizophrenia (3) 6.43
Bipolar (4) 18.01
Depression with psychotic
features (5)
1.06
Disruptive behavior
disorders
23.90
Oppositional (6) 14.09
Conduct (7) 8.08
Impulse control (8) 1.73
ADHD (9) 22.74
Stress disorders 3.17
PTSD (10) 1.60
Adjustment (14) 1.57
OCD (11) 0.23
Major depression (12) 5.72
Anxiety (13) 1.17
Other MH and/or substance disorders 3.15
Substance use (15) 0.66
Other (16) 2.49
Note: Data are from the Medicaid Analytic eXtracts (MAX) 2008, for 8 states.
ADHD ¼ attention-deficit/hyperactivity disorder; MH ¼ mental health;
OCD ¼ obsessive-compulsive disorder; PDD ¼ pervasive developmental
disorder; PTSD ¼ posttraumatic stress disorder; SSI ¼ Supplemental Security
Income.
aDiagnostic groups are hierarchical in descending order as placed in the table,
with exception of adjustment disorder, which was 14th in the hierarchy, but
presented after PTSD in order to present stress disorders as a group.
PSYCHOSOCIAL SERVICES PRIOR TO ANTIPSYCHOTIC TREATMENTlimits for the binomial distributions were reported, and logistic
regression was used to estimate the independent bivariate and
multivariate relationships.28 Speciﬁcally, unadjusted odds ratios
(ORs) were calculated with 95% CIs to determine the independent
effects of each covariate on the likelihood of receiving psychosocial
services before receiving an antipsychotic. A corresponding set
of logistic regression models was ﬁt for each stratum controlling
for all other demographic, eligibility, hospitalization, and diag-
nostic characteristics. All tests of signiﬁcance were 2-tailed. For
diagnoses, the psychotic and bipolar diagnostic category (where
ﬁrst-line use of antipsychotic medications is appropriate) was used
as the referent group for comparisons to other diagnostic
categories.
RESULTS
Characteristics of Medicaid-Enrolled Youth With a New
Start of Antipsychotics
A majority of Medicaid-enrolled children and adolescents,
aged 0 to 20 years, with a new course of antipsychotic
medications, were white, male, living in metropolitanJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 1 JANUARY 2016areas, enrolled in a Medicaid-managed care plan, and had
income-based eligibility (Table 1). Approximately one-
fourth had a diagnosis of schizophrenia, depression with
psychotic features, or bipolar disorder (BD) during the
study year. Children and adolescents with disruptive
behavioral disorders including oppositional, conduct, or
impulse control disorders represented another quarter, and
slightly less than one-fourth had ADHD without a higher-
listed disorder (Table 1). Together, young persons with
disruptive behavioral disorders and ADHD, without co-
morbid psychotic, bipolar, or developmental disorders,
comprised approximately one-half (46.4%) of the sample
with a new start of an antipsychotic.Socio-Demographic Determinants of Access to
Psychosocial Services
Overall, less than one-half of the children and adolescents
initiating antipsychotic treatment received a psychosocial
service before starting the antipsychotic (48.85%) (Table 2).www.jaacap.org 71
TABLE 2 Access to Psychosocial Services Before Initiation of Antipsychotic Treatment for Children and Adolescents in the Medicaid
Program (2008 Medicaid Analytic eXtracts [MAX] Data)
Covariates: Characteristics
New Start of AP
Denom.
Children With a Psychosocial
Service Before New Start of AP
OR 95% CI AORa 95% CINum. % 95% CI
Total 22,825 11,151 48.9 48.2e49.5
Age Group, y
0e5 1,595 625 39.2 36.8e41.6 0.61 0.54e0.67 0.69 0.62e0.77
6e11 7,823 3,936 50.3 49.2e51.4 0.95 0.90e1.01 1.07 1.01e1.14
12e17 10,617 5,471 51.5 50.6e52.5 Ref Ref
18e20 2,790 1,119 40.1 38.3e42.0 0.63 0.58e0.69 0.60 0.54e0.65
Sex
Female 8,244 4,240 51.4 50.4e52.5 1.18 1.11e1.24 1.17 1.11e1.24
Male 14,581 6,911 47.4 46.6e48.2 Ref Ref
Race/Ethnicity
White non-Hispanic 14,612 6,963 47.7 46.8e48.5 Ref Ref
African American 5,074 2,612 51.5 50.1e52.9 1.17 1.09e1.24 1.07 1.00e1.15
Hispanic 951 460 48.4 45.2e51.6 1.03 0.90e1.17 1.05 0.92e1.20
Other/Unknown 2,188 1,116 51.0 48.9e53.1 1.14 1.05e1.25 1.00 0.91e1.11
Managed Care
Enrollee 16,949 7,982 47.1 46.3e47.9 0.76 0.72e0.81 0.79 0.74e0.84
None 5,876 3,169 53.9 52.7e55.2 Ref Ref
Urbanicity
Metropolitan 15,711 7,769 49.5 48.7e50.3 Ref Ref
Non-metropolitan
urban
6,127 2,841 46.4 45.1e47.6 0.88 0.83e0.94 0.87 0.82e0.93
Rural 888 482 54.3 50.9e57.6 1.21 1.06e1.39 1.14 0.99e1.32
Aid Category
Foster 3,574 2,158 60.4 58.8e62.0 1.82 1.69e1.96 1.66 1.54e1.80
Income 12,859 5,861 45.6 44.7e46.4 Ref
Other 953 439 46.1 42.9e49.3 1.02 0.89e1.16 1.18 1.03e1.35
SSI 5,439 2,693 49.5 48.2e50.9 1.17 1.10e1.25 1.26 1.17e1.36
MH Inpatient
Hospitalization
Yes 2,786 1,477 53.0 51.1e54.9 1.21 1.12e1.31 1.01 0.93e1.10
No 20,039 9,674 48.3 47.6e49.0 Ref Ref
Diagnosis
Developmental 1,959 812 41.5 39.3e43.7 0.63 0.57e0.70 0.60 0.54e0.68
Autism and PDD (1)b 1,803 753 41.8 39.5e44.1
Tic (2)c 156 59 37.8 30.2e45.9
Psychotic/Bipolar 6,221 3,280 52.7 51.5e54.0 Ref Ref
Schizophrenia (3) 1,566 834 53.3 50.8e55.8
Bipolar (4) 4,390 2,287 52.1 50.6e53.6
Major depression with
psychosis (5)
258 155 60.1 53.8e66.1
Disruptive Behavior 5,826 3,216 55.2 53.9e56.5 1.10 1.03e1.19 1.04 0.96e1.12
Oppositional (6) 3,435 1,997 58.1 56.5e59.8
Conduct (7) 1,969 988 50.2 48.0e52.4
Impulse control (8) 422 231 54.7 49.9e59.6
ADHD (9) 5,543 2,401 43.3 42.0e44.6 0.69 0.64e0.74 0.65 0.60e0.70
Stress Disorders 773 473 61.2 57.7e64.6 1.41 1.21e1.65 1.32 1.13e1.55
PTSD (10) 390 244 62.6 57.6e67.4
Adjustment (14) 383 229 59.8 54.7e64.7
OCD (11) 57 23 40.4 27.6e54.2 0.61 0.36e1.03 0.63 0.37e1.07
Major Depression (12) 1,394 648 46.9 43.8e49.1 0.78 0.69e0.88 0.81 0.72e0.92
Anxiety (13) 284 101 35.6 30.0e41.4 0.49 0.39e0.63 0.51 0.40e0.66
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TABLE 2 Continued
Covariates: Characteristics
New Start of AP
Denom.
Children With a Psychosocial
Service Before New Start of AP
OR 95% CI AORa 95% CINum. % 95% CI
Substance/Other 768 197 25.7 22.6e28.9 0.31 0.26e0.37 0.30 0.25e0.36
Substance (15) 161 42 26.1 19.5e33.6
Other MH (16) 607 155 25.5 22.1e29.2
Note: Boldface data are statistically significant. Sample: Medicaid Analytic eXtracts (MAX) 2008, for 8 states, youth (0e20y) with new start of antipsychotic (AP) and a
mental health diagnosis. ADHD ¼ attention-deficit/hyperactivity disorder, AOR ¼ adjusted odds ratio; Denom. ¼ denominator; MH ¼ mental health;
Num. ¼ numerator; OCD ¼ obsessive-compulsive disorder; PDD ¼ pervasive developmental disorder; PTSD ¼ posttraumatic stress disorder; Ref ¼ reference group for
univariate and bivariate analysis.
aAOR: All covariates including demographic, eligibility, utilization, and diagnostic are included in adjusted models.
bDiagnostic groups: Youth were classified in hierarchical diagnostic groups 1 to 16 in descending order as positioned in the table, with exception of adjustment
disorder, which was 14th in the hierarchy, but listed after PTSD so as to present stress disorders as a group.
cTic refers to tic disorder.
PSYCHOSOCIAL SERVICES PRIOR TO ANTIPSYCHOTIC TREATMENTAmong age categories, younger children and older adoles-
cents were signiﬁcantly less likely than younger adoles-
cents to receive a psychosocial service before receiving an
antipsychotic. Females were more likely than males to
receive a psychosocial service. In non-metropolitan urban
areas, young persons were less likely to receive psycho-
social services before initiating antipsychotics than those in
metropolitan areas. Young persons in foster care were
signiﬁcantly more likely to receive psychosocial services
than those with income-related eligibility. Study patients
enrolled in Medicaid-managed care were signiﬁcantly less
likely than those in fee-for-service settings to receive psy-
chosocial treatment before antipsychotic medication.
Access to Psychosocial Services by Diagnostic Group
Diagnosis was an important predictor of receipt of psycho-
social services before initiating antipsychotic treatment
(Table 2). As compared with children and adolescents
diagnosed with psychotic or BDs, those diagnosed with
ADHD, depression, anxiety, and substance use were signif-
icantly less likely to receive a psychosocial service before
being treated with an antipsychotic medication. In addition,
children and adolescents diagnosed with pervasive devel-
opmental disorder and autism were also signiﬁcantly less
likely than those diagnosed with psychosis or BD to receive
a psychosocial service before an antipsychotic medication.
By contrast, young people diagnosed with stress disorders
were signiﬁcantly more likely than their counterparts diag-
nosed with psychotic or BDs to receive a psychosocial
intervention before receiving an antipsychotic medication
(Table 2).
DISCUSSION
In this 8-state sample of publicly insured children and ado-
lescents, less than one-half received psychotherapy or
behavioral interventions before initiation of antipsychotic
treatment. Young persons diagnosed with ADHD, depres-
sion, anxiety disorders, and substance use disorders, all
conditions without FDA-approved antipsychotic indicationsJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 1 JANUARY 2016in youth, were signiﬁcantly less likely to receive a trial of
psychosocial services before antipsychotic treatment than
corresponding youth with psychotic disorders or BD di-
agnoses. These ﬁndings suggest that antipsychotic medica-
tions are being used ahead of psychosocial services for many
young people, especially for conditions without strong
empirical support for antipsychotic efﬁcacy. Potential risks
of this service use pattern are underscored by the metabolic
risks of antipsychotics in children and adolescents and un-
certainties concerning the long-term safety of antipsychotic
medications on the developing brain.29
For many children and adolescents with ADHD and
disruptive disorders, it is likely that aggression and disrup-
tive behaviors are the clinical targets of antipsychotic treat-
ment. Clinical practice guidelines addressing the
management of aggression or disruptive disorders in chil-
dren and adolescents recommend the use of psychosocial
interventions before use of antipsychotics,22,30 including
children with autism.31 In the present study, children and
adolescents with autism and pervasive developmental dis-
orders or ADHD were less likely to receive a psychosocial
intervention before receiving antipsychotics than were youth
with psychotic or BD diagnoses. This pattern may reﬂect the
relatively more intensive mental health service use pattern
associated with childhood- or adolescent-onset BD and
schizophrenia. However, the pattern of failure to receive
psychosocial services before antipsychotic medication was
prevalent across all diagnostic categories, ranging from 37%
of cases in PTSD to 74% in substance abuse and other
disorders.
Younger children were especially unlikely to have
received psychosocial services before starting antipsychotic
medications. Only around one-third (39%) of Medicaid-
ﬁnanced young children received a psychosocial inter-
vention in the 12 weeks before starting an antipsychotic
medication. This pattern demonstrated widespread
nonconformance with the American Academy of Child and
Adolescent Psychiatry Preschool Psychopharmacology
Working Group’s recommendation for psychosocial in-
terventions before initiating any psychotropic medication inwww.jaacap.org 73
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diatricians, who may have less access to psychosocial ser-
vices, are proportionately more involved in the prescription
of antipsychotics to younger rather than older children.33
Inadequate numbers of professionals trained in evidence-
based psychosocial interventions for children and adoles-
cents, especially in rural areas, together with long waiting
lists at specialized mental health clinics that serve Medicaid
beneﬁciaries, may leave many front-line clinicians with few
options other than antipsychotics for young persons who
present with serious aggressive or disruptive behaviors.
Some subgroups were more likely to receive these
psychosocial services than others, including children and
adolescents in foster care as well as youth diagnosed with
trauma and stress disorders, including PTSD and adjust-
ment disorder. Previous reports have found that children
in foster care are more likely to receive antipsychotic
medications34-38 than other Medicaid eligibility groups, but
they are also more likely to receive services.39 This study
extends previous work by demonstrating that children and
adolescents in foster care are more likely to have received
psychosocial services before initiation of an antipsychotic.
Nevertheless, given the stresses and trauma that these
children have typically experienced, as well as the legal
and ethical responsibilities of states to ensure appropriate
care, the ﬁnding that 43% of foster care youth did not
receive psychosocial services before antipsychotic initiation
reveals an important opportunity for quality of care
improvement. For children and adolescents with PTSD,
for whom psychosocial interventions are the treatment of
choice, and there is limited evidence to support the effec-
tiveness of antipsychotics,40 nearly two-thirds (62.6%)
received at least one psychosocial intervention before
initiation of an antipsychotic.
Children and adolescents enrolled in a Medicaid-
managed care plan were less likely than those in fee-for-
service settings to receive a psychosocial intervention.
Medicaid-managed care plans, which have grown rapidly in
recent years,41 have the authority to incentivize appropriate
access to psychosocial services, and states that contract with
them have the ability to monitor their performance with
quality measures and to enforce quality and network ade-
quacy standards in this area. More study is needed to
examine the impact of increasing access to psychosocial
services before antipsychotic initiation. We do not know
what proportion of children and adolescents, if provided
psychotherapy or other psychosocial interventions early in
the course of treatment, would no longer be considered
clinical candidates for an antipsychotic. A reduction in the
use of antipsychotics may yield reduced pharmacy and
medical costs associated with adverse effects of antipsy-
chotics.42-44
More research is needed to understand the complex array
of factors that inﬂuence access and use of psychosocial
treatments for children, and to identify strategies for
improving access. Barriers to psychosocial services likely
vary with treatment setting. Prior research has demonstrated
that among Medicaid-ﬁnanced children with ADHD, psy-
chosocial services are far less commonly provided to74 www.jaacap.orgchildren treated in primary care than in specialty mental
health settings.45 Co-located mental health services, when
they are available, greatly facilitate mental health care re-
ferrals from primary care pediatricians.46 When youth are
referred by primary care physicians to outside mental health
specialists, most of them do not keep their appointments.47
In addition, many mental health practitioners have not
been trained in evidence-based interventions for youth with
disruptive behavioral problems.48 To place the current
treatment patterns in a broader context, it would be helpful
to determine rates of psychosocial service use among
Medicaid-ﬁnanced young persons before starting other
classes of psychotropic medications.
This study has several limitations. First, it is not possible
to validate the diagnoses for the study population. Second,
we used a hierarchical assignment of diagnoses that pro-
vides an opportunity to compare rates of psychosocial in-
terventions across mutually exclusive diagnostic groups.
However, different results would have been obtained had no
hierarchy been imposed. Third, we did not examine psy-
chosocial services that occurred more than 3 months before
initiation of antipsychotic medications or the extent to which
psychosocial services prevented the need to initiate anti-
psychotic medications. Fourth, we cannot observe any ser-
vices used by health care professionals who were not paid
by Medicaid, for example, psychosocial services in school,
and we do not have information on the quality or type of
psychosocial services delivered. Fifth, clinical considerations,
especially in the management of severe psychiatric disor-
ders, may necessitate initiating antipsychotic medications
before psychosocial treatments. Moreover, consensus rec-
ommendations do not support psychosocial interventions
before antipsychotic medications in conditions for which
antipsychotic medications are FDA approved. Sixth, because
Medicaid data do not include a measure of symptom
severity, it was not possible to determine the extent to which
psychosocial services preceding antipsychotic medication
use varied by this key clinical dimension. Finally, the data
were collected in 2008, and since that time, there may have
been changes in the patterns of antipsychotic treatment of
Medicaid-ﬁnanced services or their use of psychosocial
services.
The results of this study suggest that psychotherapy
and behavioral interventions are not consistently used as
ﬁrst-line treatment options for Medicaid-ﬁnanced youth
before starting antipsychotic treatment. Although many
children and adolescents receiving antipsychotics have
diagnoses for which psychotherapy is a ﬁrst-line treatment,
only a minority receive psychosocial services before initi-
ating antipsychotic medications. High rates of antipsy-
chotic use in youth with such disorders suggest that the
severity of these behaviors is often considered substantial
and that there is a pressing need to increase the availability
of psychosocial interventions, particularly evidence-based
interventions. Striking a balance between ensuring appro-
priate access to antipsychotics as needed while reinforcing
and incentivizing access to evidence-based psychosocial
interventions represents a key quality challenge for public
mental health. &JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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TABLE S1 Antipsychotic Medications Included in the Study
Drug Name Drug Brand Name
Aripiprazole Abilify
Asenapine maleate Saphris
Chlorpromazine HCl Thorazine, Chlorpromaz, Ormazine
Clozapine Clozaril, Fazaclo
Fluphenazine HCl Permitil, Prolixin
Haloperidol Haldol
Iloperidone Fanapt
Loxapine Loxitane
Olanzapine Zyprexa
Olanzapine-ﬂuoxetine HCl Symbyax
Paliperidone Invega
Perphenazine Amitriptyline, Trilafon
Perphenazine-amitriptyline Duo-Vil, Etrafon, Triavil
Pimozide Orap
Quetiapine fumarate Seroquel, Seroquel XR
Risperidone Risperdal
Thiothixene Navane
Ziprasidone HCl Geodon
Note: Antipsychotic medications that were not approved by the Food and Drug
Administration for sale (for any indication) or were not on market in the
United States in 2008 were excluded from analysis; for example, lurasidone
(Latuda) was approved in 2010, and thioridazine HCl (Mellaril) was
withdrawn from the market in 2005.
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TABLE S2 Hierarchical Diagnostic Categories and Associated International Classification of Diseases–Ninth Edition (ICD-9) Codes
9 Diagnostic
Categories Used
for Calculating ORs
Order of
Hierarchical
Assignment of
Diagnosisa
16 Diagnostic
Groups
Used for
Hierarchical
Assignment ICD-9 Codes Diagnoses Associated With ICD-9 Codes
Developmental and
Tic Disorders
1 Autism and PDD (299) Autistic disorder
2 Tic disorders (3072) Tics
Psychotic and Bipolar
Disorders
3 Schizophrenia (295,
297, 298)
Schizophrenic, delusional disorder, other nonorganic psychoses
4 Bipolar (2960, 2961,
2964-2968
excl. 29682,
30113)
Bipolar single manic episode, manic recurrent episode, current
bipolar manic episode, current bipolar mixed, current bipolar
unspeciﬁed, other bipolar unspeciﬁed excluding atypical
depressive disorder, cyclothymic disorder
5 Depression with
psychotic features
(29624,
29634)
Major depressive affective disorder single episode severe with
psychotic behavior, major depressive affective disorder
recurrent episode severe with psychotic behavior
DBDs
6 Oppositional (31381) Oppositional deﬁant disorder
7 Conduct (312 excl.
3123, 3142)
Disturbance of conduct not elsewhere classiﬁed excl. disorders
of impulse control not elsewhere classiﬁed, hyperkinetic CD
8 Impulse Control (3123) Disorders of impulse control not elsewhere classiﬁed
ADHD 9 ADHD (314
excl. 3142)
Hyperkinetic syndrome of childhood excl. hyperkinetic CD
Stress Disorders
10 PTSD (30981) PTSD
14 Adjustment (3090, 3091,
30921,
30924-
30929,
3093,
3094, 3099)
Adjustment disorder with depressed mood, prolonged
depressive reaction, separation anxiety disorder, adjustment
disorder anxiety, adjustment disorder mixed anxiety and
depressed mood, other adjustment reactions with
predominant disturbance of other emotions, adjustment
disorder disturbance of conduct, adjustment disorder
mixed disturbance of emotions and conduct,
unspeciﬁed adjustment reaction.
OCD 11 OCD (3003) OCDs
Major Depression 12 Major Depression (2962 excl.
29624, 2963
excl. 29634,
29682,
3004, 311)
Major depressive single episode excl. major depressive
affective single episode severe with psychotic behavior, MDD
recurrent episode excl. major depressive affective recurrent
episode severe with psychotic behavior, atypical depressive
disorder, dysthymic disorder, depressive disorder, not
elsewhere classiﬁed
Anxiety 13 Anxiety (3000,
3002, 308)
Anxiety states, phobic disorders, acute reaction to stress
Other MH and/or
Substance Disorders
15 Substance Use (291, 292,
303,
304, 305)
Alcohol-induced mental disorders, drug-induced mental
disorders, alcohol dependence syndrome, drug dependence,
nondependent abuse of drugs
16 Other All dx between 290 and 316 except above mentioned
Note: ADHD ¼ attention-deficit/hyperactivity disorder; CD ¼ conduct disorder; DBD ¼ disruptive behavior disorder; dx ¼ diagnosis; MDD ¼ major depressive disorder;
MH ¼ mental health; OCD ¼ obsessive-compulsive disorder; PDD ¼ pervasive developmental disorder; PTSD ¼ posttraumatic stress disorder.
aDiagnostic groups are hierarchical in descending order as placed in the table, with the exception of adjustment disorder, which was 14th in the hierarchy, but
presented after PTSD to present stress disorders as a group.
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TABLE S3 Current Procedural Terminology (CPT) Codes Used to Identify Psychosocial Services
CPT Code Code Description
90804 Ofﬁce/OP Insight, Beh. Mod., or Supportive Psychotherapy, 20e30 min.
90805 Ofﬁce/OP Insight, Beh. Mod., or Supportive Psychotherapy, 20e30 min. (w/eval. and mgmt.)
90806 Ofﬁce/OP Insight, Beh. Mod., or Supportive Psychotherapy, 45e50 min.
90807 Ofﬁce/OP Insight, Beh. Mod., or Supportive Psychotherapy, 45e50 min. (w/eval. and mgmt.)
90808 Ofﬁce/OP Insight, Beh. Mod., or Supportive Psychotherapy, 75e80 min.
90809 Ofﬁce/OP Insight, Beh. Mod., or Supportive Psychotherapy, 75e80 min. (w/eval. and mgmt.)
90810 Ofﬁce/OP Interactive Psychotherapy, 20e30 min.
90811 Ofﬁce/OP Interactive Psychotherapy, 20e30 min. (w/eval. and mgmt.)
90812 Ofﬁce/OP Interactive Psychotherapy, 45e50 min.
90813 Ofﬁce/OP Interactive Psychotherapy, 45e50 min. (w/eval. and mgmt.)
90814 Ofﬁce/OP Interactive Psychotherapy, 75e80 min.
90815 Ofﬁce/OP Interactive Psychotherapy, 75e80 min. (w/eval. and mgmt.)
90845 Other Psychotherapy, Psychoanalysis
90846 Other Psychotherapy, Family Psychotherapy (wo/patient present)
90847 Other Psychotherapy, Family Psychotherapy (w/patient present)
90849 Other Psychotherapy, Multiple-family Group Psychotherapy
90853 Other Psychotherapy, Group Psychotherapy (other than multiple family-group)
90857 Other Psychotherapy, Interactive Group Psychotherapy
90875 Individual Psychophysiological Psychotherapy, 20e30 min.
90876 Individual Psychophysiological Psychotherapy, 45e50 min.
90880 Hypnotherapy
HCPCS Code Description
H2017 Psychosocial Rehabilitation Services, per 15 Minutes
H2018 Psychosocial Rehabilitation Services, per Diem
H2019 Therapeutic Behavioral Services, per 15 Minutes
H2020 Therapeutic Behavioral Services, per Diem
H0032 Mental Health Service Plan Development By Non-Physician
H0035 Mental Health Partial Hospitalization, Treatment, Less Than 24 Hours
H0036 Community Psychiatric Supportive Treatment, Face-To-Face, per 15 Minutes
H0037 Community Psychiatric Supportive Treatment Program, per Diem
H0038 Self-Help/Peer Services, per 15 Minutes
H0039 Assertive Community Treatment, Face-To-Face, per 15 Minutes
H0040 Assertive Community Treatment Program, per Diem
H0045 Respite Care Services, Not In Home, per Diem
H0046 Mental Health Services, Not Otherwise Speciﬁed
H2001 Rehabilitation Program, per Half Day
H2010 Comprehensive Medication Services, per 15 Minutes
H2011 Crisis Intervention Service, per 15 Minutes
H2012 Behavioral Health Day Treatment, per Hour
H2013 Psychiatric Health Facility Service, per Diem
Note: Beh. Mod. ¼ behavior modification; eval. ¼ evaluation; mgmt. ¼ management.
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